Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What's Next For Bristol's Opdivo/Yervoy Combination

This article was originally published in The Pink Sheet Daily

Executive Summary

Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.

Advertisement

Related Content

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel